F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  European Journal of Pharmacology

• Publication date

  2006-02-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.EJPHAR.2005.12.026PMID 16438957
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structural Mimicry in Class A G Protein-coupled Receptor Rotamer Toggle Switches

  2004cited by this paper
• Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist

  2004cited by this paper
• An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.

  2003cited by this paper
• Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain.

  2002cited by this paper
• Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.

  2002cited by this paper
• 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor

  2001cited by this paper
• Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.

  2000cited by this paper
• Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.

  1999cited by this paper
• Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.

  1999cited by this paper
• LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation.

  1998cited by this paper
• Pharmacology of cannabinoid CB1 and CB2 receptors.

  1997cited by this paper
• Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Augments cAMP Accumulation in Striatal Neurons: Evidence for a Gs Linkage to the CB1 Receptor

  1997cited by this paper
• A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1

  1997cited by this paper
• Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells.

  1997cited by this paper
• Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system.

  1996cited by this paper
• Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.

  1996cited by this paper
• Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity.

  1995cited by this paper
• Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor

  1995cited by this paper
• Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1.

  1995cited by this paper
• Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.

  1995cited by this paper
• SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

  1994cited by this paper
• Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor.

  1993cited by this paper
• Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

  1992cited by this paper
• Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor.

  1992cited by this paper
• Molecular cloning of a human cannabinoid receptor which is also expressed in testis.

  1991cited by this paper
• Structure of a cannabinoid receptor and functional expression of the cloned cDNA

  1990cited by this paper
• Calculating receptor number from binding experiments using same compound as radioligand and competitor.

  1989cited by this paper

• Aromatic amino acids in the orthosteric region regulate cannabinoid receptor 1 conformation transitions

  2025cites this paper
• Revealing the Mechanism of Agonist-Mediated Cannabinoid Receptor 1 (CB1) Activation and Phospholipid-Mediated Allosteric Modulation.

  2019cites this paper
• Structural Insights from Recent CB1 X-Ray Crystal Structures

  2018cites this paper
• Cannabinoids: structures, effects, and classification

  2015cites this paper
• Current Cannabinoid Receptor Nomenclature and Pharmacological Principles

  2013cites this paper
• Cannabinoid receptors: nomenclature and pharmacological principles.

  2012cites this paper
• Identification of Essential Cannabinoid-binding Domains

  2011cites this paper
• Human Cannabinoid 2 GPCR Ligand-interaction Landscape: Cysteine Residues Critical to Biarylpyrazole Antagonist Binding Motif and Receptor Modulation

  2011influential citation
• Distinct second extracellular loop structures of the brain cannabinoid CB1 receptor: Implication in ligand binding and receptor function

  2011cites this paper
• Cannabinoid CB(1) receptor ligand binding and function examined through mutagenesis studies of F200 and S383.

  2011cites this paper
• Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.

  2010cites this paper
• Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown.

  2010influential citation
• Understanding functional residues of the cannabinoid CB1.

  2010cites this paper
• hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.

  2010cites this paper
• Understanding Functional Residues of the Cannabinoid CB1 Receptor for Drug Discovery

  2010cites this paper
• Evaluating Cellular Impedance Assays for Detection of GPCR Pleiotropic Signaling and Functional Selectivity

  2009cites this paper
• Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions

  2009cites this paper
• Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity profile.

  2009cites this paper
• Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.

  2009cites this paper
• Indoles and related compounds as cannabinoid ligands.

  2008cites this paper
• Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation.

  2008influential citation
• Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.

  2008cites this paper
• The Pharmacology of the Cannabinoid System—A Question of Efficacy and Selectivity

  2007cites this paper
• Identification of an Efficacy Switch Region in the Ghrelin Receptor Responsible for Interchange between Agonism and Inverse Agonism*

  2007cites this paper
• Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.

  2006cites this paper